New combo therapy targets breast cancer brain metastases

NCT ID NCT07454668

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether combining the targeted drug trastuzumab deruxtecan (T-DXd) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Up to 20 participants will receive the drug by IV every three weeks along with a single session of focused radiation. The main goal is to find the best dose and check for severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Trastuzumab deruxtecan (T-DXd) and stereotactic radiosurgery (SRS)
What this could lead to
If this combination proves safe, it could lead to a new way to control brain metastases in HER2-positive breast cancer, potentially improving outcomes for patients.
What could go wrong
This is a very early Phase 1 trial with only 20 people, focused on safety and dosing. It may not show enough benefit to move forward, and side effects from the drug or radiation could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Miami Cancer Institute at Baptist Health, Inc.

    Miami, Florida, 33176, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.